FDA-Approved Antiparasitic Drugs in the 21st Century: A Success for Helminthiasis?

FDA-Approved Antiparasitic Drugs in the 21st Century: A Success for Helminthiasis?

Diseases caused by helminth infections affect more than a quarter of the population of the world, but the therapeutic arsenal is limited. The approval of moxidectin in 2018 and triclabendazole in 2019 by the FDA marked an important moment in the fight against diseases of poverty, such as helminthias...

Full description

Saved in:
Bibliographic Details
Published in:Trends in parasitology Vol. 36; no. 7; pp. 573 - 575
Main Authors: de Moraes, Josué, Geary, Timothy G.
Format: Journal Article
Language:English
Published: England Elsevier Ltd 01-07-2020
Subjects:
FDA
helminthiasis
moxidectin
triclabendazole
triclabendazole
FDA
helminthiasis
moxidectin
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Diseases caused by helminth infections affect more than a quarter of the population of the world, but the therapeutic arsenal is limited. The approval of moxidectin in 2018 and triclabendazole in 2019 by the FDA marked an important moment in the fight against diseases of poverty, such as helminthiases.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1471-4922
1471-5007
DOI:10.1016/j.pt.2020.04.005